Using a reduced leadset and deep neural network algorithms trained on more than 175 million electrocardiograms, the KAI 12L technology reportedly detects up to 35 cardiac determinations, including acute myocardial infarction.
The Food and Drug Administration (FDA) has granted dual 510(k) clearances for the pocket-sized Kardia 12L electrocardiography (ECG) system and KAI 12L artificial intelligence (AI) technology, which may bolster the detection of life-threating cardiac conditions with a reduced leadset.
Trained on more than 175 million ECGs, the deep neural network algorithms with KAI 12L may facilitate the diagnosis of 35 cardiac determinations, including common forms of cardiac ischemia and acute myocardial infarction, according to AliveCor, the developer of the technology.
Dual FDA clearances for the pocket-sized Kardia 12L ECG System (shown above) and the KAI 12L AI technology, trained on more than 175 million ECGs, may bolster the detection of cardiac conditions and facilitate use of the technology in resource-challenged health-care facilities, according to AliveCor, the developer of the modalities. (Photo courtesy of AliveCor.)
"Not only is it the first FDA-cleared AI that can detect a heart attack on a reduced leadset, but it also returns determinations for our broadest range of conditions yet," said Priya Abani, the CEO of AliveCor. "Paired with our pocket-sized Kardia 12L ECG System, this offering is poised to disrupt traditional care pathways and represents a leap forward in cardiac care."
In comparison to standard 12-lead ECG devices, the pocket-sized Kardia 12L ECG system enables clinicians to capture eight quality diagnostic bandwidth leads with five electrodes and a single cable. AliveCor added that the portability of the battery-operated, 0.3-lb. device may expand access to the technology for a variety of health-care facilities including resource-challenged centers or rural medical facilities.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
New AI-Enabled Portable Ultrasound May Facilitate 50 Percent Reduction in Cardiac Imaging Scan Time
March 28th 2025Artificial intelligence (AI)-powered measurement capabilities provide key features with the Compact Ultrasound 5500CV device, which was unveiled at the American College of Cardiology (ACC) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Predicting Diabetes on CT Scans: What New Research Reveals with Pancreatic Imaging Biomarkers
March 25th 2025Attenuation-based biomarkers on computed tomography (CT) scans demonstrated a 93 percent interclass correlation coefficient (ICC) agreement across three pancreatic segmentation algorithms for predicting diabetes, according to a study involving over 9,700 patients.